TY - JOUR
T1 - HLA-G-Treated Tolerogenic Dendritic Cells Induce Tolerogenic Potential by Increasing Expression of B7-1 (CD80) Molecules
AU - Smith, M.
AU - Bittner IV, J. G.
AU - White, S.
AU - Smith, D.
AU - Horuzsko, Anatolij
N1 - Funding Information:
We would like to thank Y.H. Chang, Y.R. Huang and J. Haupt for their help in specimen collections and C.H. Chang for assistance and advice in molecular operations. Discussions with W.Y. Lo greatly improved our manuscript. This work was supported by a grant from the National Science Council, Taiwan, ROC (NSC-92-2311-B-029-002) to I.M. Tso.
PY - 2008/6
Y1 - 2008/6
N2 - Background: By consensus, HLA-G has a role in the induction of tolerance via interaction with dendritic cells and manipulation of co-stimulatory molecule expression. The purpose of this study was to demonstrate that HLA-G modified dendritic cells exhibit a decreased ability to stimulate T-cells in vitro due to increased expression of B7-1, which provides regulatory signalling to T-cells as a consequence of binding CD28 and CD152 ligands. Methods: Bone-marrow cells were cultured from Brown Norway (BN) rat femurs and sorted with anti-rat dendritic cell Ab (OX62) microbeads. Isolated dendritic cells (DCs) were treated with HLA-G tetramer for 3 days. Initially, cells were plated with media, alloantigenic splenocytes, and T-cells and then observed in mixed lymphocyte reaction for thymidine uptake. Also, the cells were analyzed by flow cytometry using antibodies for MHC-II (IA), CD80, and CD86. Results: This study displays that HLA-G-modified DCs decrease induction of an alloproliferative response. In addition, this study demonstrated that HLA-G tetramer treatment decreases CD86 and permits expression of CD80 without altering MHC-II expression. Discussion: This study specifically investigated the role of B7-1 (CD80), showing that HLA-G treatment of immature DCs allows expression of B7-1 (CD80) without altering MHC-II expression and simultaneously decreases B7-2 (CD86) expression. Therefore, a low level of B7-2 (CD86) allows attenuation of T-cell response after activation, both of which are beneficial to immune tolerance. The selective expression of B7-1 (CD80) is important and may serve as a guide for future therapies aimed at transplant tolerance.
AB - Background: By consensus, HLA-G has a role in the induction of tolerance via interaction with dendritic cells and manipulation of co-stimulatory molecule expression. The purpose of this study was to demonstrate that HLA-G modified dendritic cells exhibit a decreased ability to stimulate T-cells in vitro due to increased expression of B7-1, which provides regulatory signalling to T-cells as a consequence of binding CD28 and CD152 ligands. Methods: Bone-marrow cells were cultured from Brown Norway (BN) rat femurs and sorted with anti-rat dendritic cell Ab (OX62) microbeads. Isolated dendritic cells (DCs) were treated with HLA-G tetramer for 3 days. Initially, cells were plated with media, alloantigenic splenocytes, and T-cells and then observed in mixed lymphocyte reaction for thymidine uptake. Also, the cells were analyzed by flow cytometry using antibodies for MHC-II (IA), CD80, and CD86. Results: This study displays that HLA-G-modified DCs decrease induction of an alloproliferative response. In addition, this study demonstrated that HLA-G tetramer treatment decreases CD86 and permits expression of CD80 without altering MHC-II expression. Discussion: This study specifically investigated the role of B7-1 (CD80), showing that HLA-G treatment of immature DCs allows expression of B7-1 (CD80) without altering MHC-II expression and simultaneously decreases B7-2 (CD86) expression. Therefore, a low level of B7-2 (CD86) allows attenuation of T-cell response after activation, both of which are beneficial to immune tolerance. The selective expression of B7-1 (CD80) is important and may serve as a guide for future therapies aimed at transplant tolerance.
UR - http://www.scopus.com/inward/record.url?scp=45449108998&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=45449108998&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2008.01.062
DO - 10.1016/j.transproceed.2008.01.062
M3 - Article
C2 - 18589158
AN - SCOPUS:45449108998
SN - 0041-1345
VL - 40
SP - 1598
EP - 1603
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 5
ER -